Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas
文献类型：期刊论文
| 作者 | Lin, Yi2,3; Jiang, Tao1,2; Zhou, Kaijia2; Xu, Li2; Chen, Baoshi2; Li, Guilin2; Qiu, Xiaoguang2; Jiang, Tianzi ; Zhang, Wei4; Song, Sonya W.1
|
| 刊名 | NEURO-ONCOLOGY
 |
| 出版日期 | 2009-10-01 |
| 卷号 | 11期号:5页码:468-476 |
| 关键词 | glioma IGFBP-2 plasma surrogate biomarker prognosis recurrence |
| 英文摘要 | Insulin-like growth factor binding protein 2 (IGFBP-2) is a malignancy-associated protein measurable in tumors and blood. Increased IGFBP-2 is associated with shortened survival of advanced glioma patients. Thus, we examined plasma IGFBP-2 levels in glioma patients and healthy controls to evaluate its value as a plasma biomarker for glioma. Plasma IGFBP-2 levels in 196 patients with newly diagnosed glioma and 55 healthy controls were analyzed using an IGFBP-2 ELISA kit. Blood was collected before surgery, after two-cycle adjuvant chemotherapy, and at recurrence. Plasma IGFBP-2 levels were correlated with disease-free survival DFS) using Cox regression analyses. We found that preoperative plasma IGFBP-2 levels were significantly higher in high-grade glioma patients n = 43 for grade III glioma; n = 72 for glioblastoma multiforme [GBM]) than in healthy controls n = 55; p < 0.001) and low-grade (grade II) glioma patients n 5 81; p, 0.001). No significant differences in preoperative plasma IGFBP-2 levels were observed between grade III glioma and GBM patients or between grade II glioma patients and healthy controls. After recurrence, plasma IGFBP-2 levels were significantly increased in GBM patients (n = 26; p < 0.001). Preoperative plasma IGFBP-2 levels were significantly correlated with DFS in GBM patients ( hazard ratio, 1.404; 95% confidence interval, 1.078-1.828; p = 0.012). We conclude that preoperative plasma IGFBP-2 levels are significantly higher in high-grade glioma patients than in low-grade glioma patients and healthy subjects, and are significantly correlated with recurrence and DFS in patients with GBM. Longitudinal studies with a larger study population are needed to confirm these findings. Neuro-Oncology 11, 468-476, 2009 (Posted to Neuro-Oncology [serial online], Doc. D08-00199, January 22, 2009. URL http://neuro-oncology. dukejournals. org; DOI: 10.1215/15228517-2008-114) |
| WOS标题词 | Science & Technology ; Life Sciences & Biomedicine |
| 类目[WOS] | Oncology ; Clinical Neurology |
| 研究领域[WOS] | Oncology ; Neurosciences & Neurology |
| 关键词[WOS] | FACTOR-BINDING PROTEIN-2 ; POTENTIAL SERUM MARKER ; GROWTH-FACTOR-I ; PROSTATE-CANCER ; GLIOBLASTOMA-MULTIFORME ; MOLECULAR SUBTYPES ; OVARIAN-CANCER ; EXPRESSION ; PROGRESSION ; INSULIN-LIKE-GROWTH-FACTOR-BINDING-PROTEIN-2 |
| 收录类别 | SCI |
| 语种 | 英语 |
| WOS记录号 | WOS:000270494800002 |
| 源URL | [http://ir.ia.ac.cn/handle/173211/3130]  |
| 专题 | 自动化研究所_脑网络组研究中心 |
| 作者单位 | 1.Chinese Acad Sci, LIAMA Ctr Computat Med, Natl Lab Pattern Recognit, Inst Automat, Beijing, Peoples R China 2.Capital Med Univ, Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China 3.China Med Univ, Dept Neurosurg, Affiliated Hosp 1, Shenyang, Peoples R China 4.Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA |
| 推荐引用方式 GB/T 7714 | Lin, Yi,Jiang, Tao,Zhou, Kaijia,et al. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas[J]. NEURO-ONCOLOGY,2009,11(5):468-476. |
| APA | Lin, Yi.,Jiang, Tao.,Zhou, Kaijia.,Xu, Li.,Chen, Baoshi.,...&Song, Sonya W..(2009).Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas.NEURO-ONCOLOGY,11(5),468-476. |
| MLA | Lin, Yi,et al."Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas".NEURO-ONCOLOGY 11.5(2009):468-476. |
入库方式： OAI收割
来源：自动化研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。